Cargando…
Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Diabetes Association
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943277/ https://www.ncbi.nlm.nih.gov/pubmed/31902151 http://dx.doi.org/10.4093/dmj.2019.0213 |
| _version_ | 1783484855843028992 |
|---|---|
| author | Hwang, You-Cheol |
| author_facet | Hwang, You-Cheol |
| author_sort | Hwang, You-Cheol |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6943277 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Korean Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69432772020-01-09 Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) Hwang, You-Cheol Diabetes Metab J Response Korean Diabetes Association 2019-12 2019-12-26 /pmc/articles/PMC6943277/ /pubmed/31902151 http://dx.doi.org/10.4093/dmj.2019.0213 Text en Copyright © 2019 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Response Hwang, You-Cheol Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title | Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title_full | Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title_fullStr | Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title_full_unstemmed | Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title_short | Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title_sort | response: comparison of the efficacy of rosuvastatin monotherapy 20 mg with rosuvastatin 5 mg and ezetimibe 10 mg combination therapy on lipid parameters in patients with type 2 diabetes mellitus (diabetes metab j 2019;43:582–9) |
| topic | Response |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943277/ https://www.ncbi.nlm.nih.gov/pubmed/31902151 http://dx.doi.org/10.4093/dmj.2019.0213 |
| work_keys_str_mv | AT hwangyoucheol responsecomparisonoftheefficacyofrosuvastatinmonotherapy20mgwithrosuvastatin5mgandezetimibe10mgcombinationtherapyonlipidparametersinpatientswithtype2diabetesmellitusdiabetesmetabj2019435829 |